


**Product Name** : Foretinib  
**Cat. No.** : PC-42535  
**CAS No.** : 849217-64-7  
**Molecular Formula** : C<sub>34</sub>H<sub>34</sub>F<sub>2</sub>N<sub>4</sub>O<sub>6</sub>  
**Molecular Weight** : 632.6537  
**Target** : c-Met (HGFR)  
**Solubility** : DMSO: ≥ 38 mg/mL



## Biological Activity

Foretinib (XL880, GSK1363089, GSK089, EXEL-2880) is a potent, multikinase inhibitor that inhibits **c-Met** and **VEGFR**, also inhibits KIT, Flt-3, PDGFR $\beta$ , and Tie-2.

Foretinib inhibits HGFR family tyrosine kinases with IC<sub>50</sub> of 0.4 nM for Met and 3 nM for Ron, also inhibits KDR, Flt-1, and Flt-4 with IC<sub>50</sub> of 0.9, 6.8, and 2.8 nM, respectively.

Foretinib exhibits modest activity against FGFR1 and EGFR, no activity against 50 serine/threonine kinases, including CDKs and PKC isoforms.

Foretinib inhibits cellular HGF-induced Met phosphorylation and VEGF-induced ERK phosphorylation and prevents both HGF-induced responses of tumor cells and HGF/VEGF-induced responses of endothelial cells.

Foretinib exhibits significant inhibition of tumor burden in animal model of lung metastasis.

## References

Qian F, et al. *Cancer Res.* 2009 Oct 15;69(20):8009-16.

Liu L, et al. *Cancer Res.* 2009 Sep 1;69(17):6871-8.

Eder JP, et al. *Clin Cancer Res.* 2010 Jul 1;16(13):3507-16.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com